NNNN — Anbio Biotechnology Class A Ordinary Shares stock price, charts and financials

QT29Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
5.60
+0.02+0.36%
NNNNQT29Anbio Biotechnology Class A Ordinary Shares·NASDAQ
5.60+0.36%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E29.47EPS (ttm)0.19Insider Own-Shs Outstand43.89MPerf Week-13.98%
Market Cap245.79MForward P/E-EPS next Y-Insider Trans-Shs Float39.69MPerf Month-32.93%
Enterprise Value233.79MPEG0.33EPS next Q-Inst Own-Short Float0.15%Perf Quarter-64.69%
Income8.00MP/S20.48EPS this Y-Inst Trans-Short Ratio0.66Perf Half Y-73.26%
Sales12.00MP/B8.19EPS next Y-ROA28.07%Short Interest58.42KPerf YTD-81.38%
Book/sh0.68P/C20.48EPS next 5Y-ROE27.49%52W High51.33 -89.09%Perf Year-87.18%
Cash/sh0.27P/FCF0.00EPS past 3/5Y31.98% -ROIC25.46%52W Low5.25 6.67%Perf 3Y-
Dividend Est.-EV/EBITDA33.40Sales past 3/5Y-27.89% -Gross Margin86.10%Volatility8.12% 9.48%Perf 5Y-
Dividend TTM-EV/Sales19.48EPS Y/Y TTM239.29%Oper. Margin65.20%ATR (14)0.88Perf 10Y-
Dividend Ex-Date-Quick Ratio344.31Sales Y/Y TTM50.00%Profit Margin72.09%RSI (14)25.06Recom-
Dividend Gr. 3/5Y-Current Ratio344.31EPS Q/Q-SMA20-17.74%Beta0.17Target Price-
Payout0.00%Debt/Eq0.00Sales Q/Q-16.67%SMA50-34.95%Rel Volume2.26Prev Close5.58
Employees27LT Debt/Eq-EarningsJul 07SMA200-74.22%Avg Volume132.28KPrice5.60
IPO DateFeb 19, 2025Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-1.20Volume299,335Change0.36%
Latest News· Times ET
Company

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
Total Revenue1298
Cost of Goods Sold Incl. D&A112
Gross Profit1186
Selling, General and Administrative Excl. Other223
Research and Development
000
Other Operating Expense001
Operating Income862
Interest Expense
000
Unusual Expense
Non-Operating Income (Expense)010
Net Income Before Taxes862
Income Taxes
000
Consolidated Net Income862
Net Income From Continuing Operations862
Net Income862
EPS (Recurring)0.190.160.06
EPS (Basic, Before Extraordinaries)0.190.160.06
EPS (Diluted)0.190.160.06
EBITDA762
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio29.47187.94
Price To Sales Ratio20.53147.01
Gross Margin91.6788.8975.00
Operating Margin66.6766.6725.00
Net Margin66.6766.6725.00
Shares Outstanding444442
Market Capitalization2461,323
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.